Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long‐term graft‐localized immune privilege-Reference-Cited by-同舟云学术

Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long‐term graft‐localized immune privilege

Published:2020-01-05 Issue:5 Volume:20 Page:1285-1295
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Woodward Kyle B.¹²,Zhao Hong¹,Shrestha Pradeep¹^ORCID,Batra Lalit¹^ORCID,Tan Min¹,Grimany‐Nuno Orlando¹,Bandura‐Morgan Laura¹³,Askenasy Nadir⁴,Shirwan Haval¹^ORCID,Yolcu Esma S.¹^ORCID

Affiliation:

1. Department of Microbiology and Immunology Institute for Cellular TherapeuticsUniversity of Louisville Louisville Kentucky

2. Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington

3. National Science Center Krakow Poland

4. Frankel Laboratory of Experimental Bone Marrow Transplantation Petach Tikva Israel

Funder

American Diabetes Association

National Institutes of Health

W. M. Keck Foundation

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.15747

Reference61 articles.

1. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia

2. In vivo tracking of 'color-coded' effector, natural and induced regulatory T cells in the allograft response

3. Characterization of primary T cell subsets mediating rejection of pancreatic islet grafts;Gill RG;J Immunol,1989

4. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation

5. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead;Nature Reviews Endocrinology;2024-09-03

2. Genetically engineered hypoimmunogenic cell therapy;Nature Reviews Bioengineering;2024-07-29

3. Unlocking Transplant Tolerance with Biomaterials;Advanced Healthcare Materials;2024-07-03

4. Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment;Bioactive Materials;2024-07

5. Engineering Pancreatic Islets to Transiently Codisplay on Their Surface Thrombomodulin and CD47 Immunomodulatory Proteins as a Means of Mitigating Instant Blood-Mediated Inflammatory Reaction following Intraportal Transplantation;The Journal of Immunology;2024-05-06